PACAP38´s (Pituitary Adenylate Cyclase-Activating Polypeptide) Headache Inducing Characteristics and Effects on the Cerebral Blood Flow

Basic Scientific Research Investigating PACAP38 Headache Inducing Effects in Migraine Patients

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00380263

Enrollment

Registered

2006-09-25

Start date

2006-11-30

Completion date

2007-11-30

Last updated

2008-05-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Migraine Without Aura

Brief summary

To investigate headache score and accompanying symptoms during and after infusion of PACAP38 i migraine patients

Detailed description

To investigate headache score and accompanying symptoms during and after infusion of PACAP38 Changes in regional cerebral blood flow (rCBF) in the area supplied by middle cerebral artery (MCA), blood flow in MCA, diameter of the superficial temporal artery (STA) and radial artery (RA)

Interventions

DRUGPACAP38

10 pmol/kg/min given one time

Eligibility

Sex/Gender

ALL

Age

18 Years to 50 Years

Healthy volunteers

Inclusion criteria

* Healthy migraine patient without aura * Aged 18-50 * 50-100 kg * Fertile women must use safe contraceptives (IUD, oral contraceptives, surgical sterilisation and long lasting gestagen.

Exclusion criteria

* Tension type headache more than five times/month * Other primary headaches * Daily medication except contraceptives * Drug taken within 4 times the halflife for the specific drug except contraceptives * Pregnant or lactating women * Exposure to radiation within the last year * Headache within the last 48 hours before start of trial * Hypertension * Hypotension * Respiratory or cardiac disease

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026